Related Experiment Video

Updated: Aug 4, 2026

High-throughput Assay to Phenotype Salmonella enterica Typhimurium Association, Invasion, and Replication in Macrophages
11:10

High-throughput Assay to Phenotype Salmonella enterica Typhimurium Association, Invasion, and Replication in Macrophages

Published on: August 11, 2014

Effect of trimethoprim-sulphamethoxazole on typhoid and salmonella carriers

J Brodie, I A Macqueen, D Livingstone

    British Medical Journal
    |August 8, 1970
    PubMed

    Insights

    Trimethoprim-sulphamethoxazole effectively cleared Salmonella Typhi infection in a male carrier and a convalescent excretor. However, female carriers with gallbladder issues persisted as excretors, indicating treatment limitations.

    Area of Science:

    • Microbiology
    • Infectious Diseases
    • Pharmacology

    Background:

    • Typhoid fever, caused by Salmonella Typhi, poses a significant public health challenge.
    • Chronic typhoid carriers are a reservoir for disease transmission.
    • Gallbladder abnormalities are frequently associated with chronic Salmonella Typhi carriage.

    Purpose of the Study:

    • To evaluate the efficacy of trimethoprim-sulphamethoxazole in treating chronic typhoid carriers.
    • To assess the impact of gallbladder abnormalities on treatment outcomes.

    Main Methods:

    • Treatment of four chronic typhoid carriers with trimethoprim-sulphamethoxazole.
    • Monitoring of bacterial excretion post-treatment.
    • Inclusion of a convalescent excretor and two other Salmonella carriers for comparison.

    Main Results:

    • The male chronic carrier was cleared of infection.
    • Three female chronic carriers with gallbladder abnormalities remained excretors.
    • A convalescent excretor and two other Salmonella carriers (one chronic for 24 years) were cleared of infection.

    Conclusions:

    • Trimethoprim-sulphamethoxazole shows potential for treating typhoid carriers but may be less effective in individuals with gallbladder abnormalities.
    • Gallbladder status is a critical factor influencing the success of antibiotic therapy for typhoid carriers.

    More Related Videos

    Chronic Salmonella Infection Induced Intestinal Fibrosis08:40

    Chronic Salmonella Infection Induced Intestinal Fibrosis

    Published on: September 22, 2019

    Characterizing Salmonella Typhimurium-induced Septic Peritonitis in Mice14:10

    Characterizing Salmonella Typhimurium-induced Septic Peritonitis in Mice

    Published on: July 29, 2022

    Related Concept Videos

    Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

    Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

    Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

    Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Microbiota Modulation by Antibiotics01:21

    Microbiota Modulation by Antibiotics

    Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
    Clinical Significance of Antibiotic Resistance01:25

    Clinical Significance of Antibiotic Resistance

    Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
    Antiprotozoal Agents01:21

    Antiprotozoal Agents

    Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...